<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278512</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD Vasculitis.Auto2002</org_study_id>
    <nct_id>NCT00278512</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Support in Vasculitis</brief_title>
  <official_title>High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The systemic vasculitis is a wide-ranging group of diseases that are characterized by the&#xD;
      presence of blood vessel inflammation (1). Despite this common feature, each type of&#xD;
      vasculitis has a unique variety of clinical manifestations that influences its degree of&#xD;
      disease severity and ultimately its management. Immunosuppressive therapy forms the&#xD;
      foundation of treatment for almost all forms of systemic vasculitis.&#xD;
&#xD;
      The systemic necrotizing vasculitis (SNV) are a subset of vasculitis with significant&#xD;
      morbidity and mortality (2). The SNV are Wegener's granulomatosis, allergic angiitis and&#xD;
      granulomatosis (AAG) (also known as Churg-Strauss syndrome), polyarteritis nodosum (PAN),&#xD;
      microscopic polyangiitis (MPA), and overlap syndrome. In spite of modern therapeutic immune&#xD;
      suppressive agents, there remains a not inconsequential morbidity and mortality associated&#xD;
      with SNV. The current standard therapy for SNV is chronic oral cyclophosphamide (1-3&#xD;
      mg/kg/day) and corticosteroids (3-6). Transplant doses of cyclophosphamide at 200 mg/kg&#xD;
      infused over 4 days is the most common worldwide transplant regimen for systemic lupus&#xD;
      erythematosus (SLE) (7). Like SLE, SNV are cyclophosphamide responsive disease. We,&#xD;
      therefore, propose a trial of high dose cyclophosphamide with anti-thymocyte globulin (ATG)&#xD;
      for patients with SNV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selection of High Dose Immunosuppressive Therapy and Autologous HSCT Strategy for this Trial&#xD;
&#xD;
      Selection of the Regimen for High-Dose Immunosuppressive Therapy Cyclophosphamide with ATG&#xD;
      (Cy/ATG) is a common conditioning regimen with two decades of experience in the treatment of&#xD;
      aplastic anemia and has been used safely without reported mortality in the treatment of&#xD;
      autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Cy/ATG not&#xD;
      only has less acute toxicity, it has less chronic side effects. Cy/ATG is not associated with&#xD;
      late malignancies or cataracts. Cyclophosphamide and anti-thymocyte globulin (horse or rabbit&#xD;
      ATG) and rituximab are potent immunosuppressive agents. Rituximab and ATG contribute&#xD;
      additional immunosuppression without additional cytotoxicity. Rituximab and ATG given shortly&#xD;
      pre-transplant will contribute to the elimination of host T lymphocytes that survive&#xD;
      cyclophosphamide or that contaminate the CD34+selected graft. SLE, an autoimmune disease&#xD;
      responsive to cyclophosphamide, responds well to a Cy/ATG/rituximab conditioning regimen. For&#xD;
      these reasons, Cy/ATG/rituximab will be the conditioning regimen utilized in this study.&#xD;
&#xD;
      To justify any new therapy such as HSCT, the risk of dying from the disease must be higher&#xD;
      than that expected from its treatment, or the morbidities associated with the disease must&#xD;
      justify the treatment risks. Autologous stem cell transplantation has a mortality of 1-3% in&#xD;
      breast cancer patients using intense conditioning regimens with multiple alkylating agents,&#xD;
      and up to 10-15% in patients with lymphomas and other malignancies. The latter patients&#xD;
      usually have been heavily treated before transplant and the accumulation of treatment&#xD;
      toxicities is thought to play a role in their increased transplant-related mortality.&#xD;
      Cyclophosphamide and ATG/rituximab have been used to transplant of extremely ill patients&#xD;
      with systemic lupus erythematosus and multiple organ dysfunction at Northwestern University&#xD;
      without mortality.&#xD;
&#xD;
      Since patients in this study are earlier in the disease course, a conditioning regimen that&#xD;
      has historically been associated with less toxicity will be employed. The regimen will be&#xD;
      Cyclophosphamide at 200 mg/kg with ATG 5.5 mg/kg and rituximab 1000 mg divided over 2 doses.&#xD;
      Cyclophosphamide 200mg/kg with or without ATG has been used safely and effectively in a&#xD;
      variety of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis,&#xD;
      and aplastic anemia. Rabbit ATG will be used instead of equine ATG due to the lower incidence&#xD;
      of hypersensitivity and fever with rabbit ATG compared to equine.&#xD;
&#xD;
      Method of Harvesting Stem Cells Based on the experience of the pilot studies, the current&#xD;
      protocol will mobilize stem cells with cyclophosphamide and granulocyte-colony stimulating&#xD;
      factor (G-CSF), and collect stem cells by apheresis, with subsequent bone marrow harvest&#xD;
      performed only if needed to supplement the peripheral blood stem cells (PBSC). Based on&#xD;
      experience of autoimmune flares in patients receiving G-CSF alone for mobilization (56),&#xD;
      patients will be mobilized with cyclophosphamide 2.0 g/m2 and G-CSF 10 mcg /kg.&#xD;
&#xD;
      Regimen for Autologous HSCT&#xD;
&#xD;
      Cyclophosphamide Cyclophosphamide is an active agent in patients with a wide variety of&#xD;
      malignancies. It is used frequently in the therapy of lymphoid malignancies and has potent&#xD;
      immunosuppressive activity. It is frequently used as a cytotoxic and immunosuppressive agent&#xD;
      in patients undergoing marrow transplants and as a treatment for patients with autoimmune&#xD;
      diseases. It is an alkylating agent that requires hepatic metabolism to the active&#xD;
      metabolites, phosphoramide mustard and acrolein. These active metabolites react with&#xD;
      nucleophilic groups. It is available as an oral or intravenous preparation. Bioavailability&#xD;
      is 90% when given orally. The half-life of the parent compound is 5.3 hours in adults, and&#xD;
      the half-life of the major metabolite phosphoramide mustard is 8.5 hours. Liver or renal&#xD;
      dysfunction will lead to prolonged serum half-life. CY is administered intravenously at a&#xD;
      dosage of 50 mg/kg on each of two successive days (use adjusted ideal body weight if&#xD;
      patient's actual body weight is greater than 100% ideal body weight). The major dose limiting&#xD;
      side effect at high doses is cardiac necrosis. Hemorrhagic cystitis can occur and is mediated&#xD;
      by the acrolein metabolite. This can be prevented by co-administration of MESNA or bladder&#xD;
      irrigation. Other notable side effects include nausea, vomiting, alopecia, myelosuppression&#xD;
      and SIADH. Refer to institutional manuals for more information about administration, toxicity&#xD;
      and complications.&#xD;
&#xD;
      Rabbit-Derived Anti-Thymocyte Globulin (ATG) Rabbit-derived anti-thymocyte globulin (ATG) is&#xD;
      a gamma globulin preparation obtained from hyperimmune serum of rabbits immunized with human&#xD;
      thymocytes. ATG has been used predominately in solid organ transplant immunosuppressive&#xD;
      regimens. ATG is a predominantly lymphocyte-specific immunosuppressive agent. It contains&#xD;
      antibodies specific to the antigens commonly found on the surface of T cells. After binding&#xD;
      to these surface molecules, ATG promotes the depletion of T cells from the circulation&#xD;
      through mechanisms, which include opsonization and complement-assisted, antibody- dependent,&#xD;
      cell-mediated cytotoxicity. The plasma half-life ranges from 1.5-12 days. ATG is administered&#xD;
      intravenously at a dose of 0.5 mg/kg recipient body weight on day -6 and a dose of 1.0 mg/kg&#xD;
      recipient body weight on days -5, -4, -3, -2 and -1. Unlike equine ATG, rabbit ATG does not&#xD;
      require a pre-infusion skin test to check for hypersensitivity. Methylprednisolone 1 gram&#xD;
      will be given before every dose of ATG. Additional medications such as diphenhydramine may be&#xD;
      given at the discretion of the attending physician. Although rare, the major toxicity is&#xD;
      anaphylaxis. Chills, fever, pruritus or serum sickness may occur.&#xD;
&#xD;
      Regimen for allogeneic HSCT&#xD;
&#xD;
      Cyclophosphamide (Cytoxan) Cyclophosphamide (CY) is administered intravenously at a dosage of&#xD;
      50 mg/kg on each of four successive days (use adjusted ideal body weight if patient's actual&#xD;
      body weight is greater than 100% ideal body weight). The major dose limiting side effect at&#xD;
      high doses is cardiac necrosis. Hemorrhagic cystitis can occur and is mediated by the&#xD;
      acrolein metabolite. This can be prevented by co-administration of MESNA or bladder&#xD;
      irrigation. Other notable side effects include nausea, vomiting, alopecia, myelosuppression&#xD;
      and SIADH. Refer to institutional manuals for more information about administration, toxicity&#xD;
      and complications.&#xD;
&#xD;
      Fludarabine Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then&#xD;
      phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate,&#xD;
      2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha,&#xD;
      ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of&#xD;
      action of this antimetabolite is not completely characterized and may be multi-faceted.&#xD;
&#xD;
      Phase I studies in humans have demonstrated that fludarabine phosphate is rapidly converted&#xD;
      to the active metabolite, 2-fluoro-ara-A, within minutes after intravenous infusion.&#xD;
      Consequently, clinical pharmacology studies have focused on 2-fluoro-ara-A pharmacokinetics.&#xD;
      After the five daily doses of 25 mg 2-fluoro-ara-AMP/m2 to cancer patients infused over 30&#xD;
      minutes, 2-fluoro-ara-A concentrations show a moderate accumulation. During a 5-day treatment&#xD;
      schedule, 2-fluoro-ara-A plasma trough levels increased by a factor of about 2. The terminal&#xD;
      half-life of 2-fluoro-ara-A was estimated as approximately 20 hours. In vitro, plasma protein&#xD;
      binding of fludarabine ranged between 19% and 29%.&#xD;
&#xD;
      CAMPATH Campath-1H is a humanized fusion protein that is directed to CD52 antigen that is&#xD;
      expressed on all lymphocytes, monocytes and macrophages. It has very potent immunosuppressive&#xD;
      property and is effective for prevention of graft-versus-host disease. 30 mg/day of CAMPATH&#xD;
      will be given intravenously over 2 hours on days -4, -3 and -2. The most commonly reported&#xD;
      adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash,&#xD;
      tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and&#xD;
      infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency&#xD;
      of infusion reactions was highest in the first week of treatment. Other commonly reported&#xD;
      adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly&#xD;
      reported serious adverse reactions are cytopenias, infusion reactions, and&#xD;
      immunosuppression/infections. About 30 minutes before the patient gets Campath, he/she will&#xD;
      be given other medications (such as acetaminophen or diphenhydramine, given orally, not IV)&#xD;
      to help reduce side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No participant enrolled over five years. No plan to continue the study.&#xD;
  </why_stopped>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Vasculitis</condition>
  <arm_group>
    <arm_group_label>Autologous Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Stem Cell Transplant will be performed on eligible patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic Stem Cell Transplant will be performed on eligible patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cell Transplant</intervention_name>
    <description>Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning</description>
    <arm_group_label>Autologous Stem Cell Transplant</arm_group_label>
    <other_name>AutologousHematopoietic Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Stem Cell Transplant</intervention_name>
    <description>Allogeneic Stem Cell Transplant will be performed after conditioning</description>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <arm_group_label>Autologous Stem Cell Transplant</arm_group_label>
    <other_name>Allogeneic Hematopoietic Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Causes prevention of the cell division</description>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <arm_group_label>Autologous Stem Cell Transplant</arm_group_label>
    <other_name>Cytoxan, Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG (rabbit)</intervention_name>
    <description>A rabbit polyclonal antibody to lymphocyte</description>
    <arm_group_label>Autologous Stem Cell Transplant</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Hematopoietic growth factor</description>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <arm_group_label>Autologous Stem Cell Transplant</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath-1h</intervention_name>
    <description>Humanized monoclonal antibody against CD52 antigen</description>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>inhibits DNA synthesis or repair</description>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>immune suppressive drug</description>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <other_name>FK506, PROGRAF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs</description>
    <arm_group_label>Allogeneic Stem Cell Transplant</arm_group_label>
    <arm_group_label>Autologous Stem Cell Transplant</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age 16 to 60 years old at the time of pretransplant evaluation.&#xD;
&#xD;
          -  2. An established diagnosis of systemic necrotizing vasculitis (Wegener's&#xD;
             granulomatous, polyarteritis nodosum (PAN), allergic angiitis granulomatous (AAG, also&#xD;
             known as Churg Strauss syndrome), microscopic polyangiitis (MPA), or overlap&#xD;
             syndrome)Temporal arteritis, or mixed cryoglobulinemia or primary central nervous&#xD;
             system vasculitis AND failure of corticosteroids and any of the following at least 6&#xD;
             months of oral or IV cytoxan, rituximab, or cellcept. (Failure defined as: a) patients&#xD;
             with a high disease activity and involvement of internal organs as measured by&#xD;
             increased FFS &gt; 2 and/or BVAS &gt; 20, or b) patients who develop recurrent flares with&#xD;
             subsequent progressive organ damage.)&#xD;
&#xD;
        OR&#xD;
&#xD;
        Neurovascular Behcets with recurrent oral and/or genital lesions confirmed by culture to be&#xD;
        herpes negative, MRI findings consistent with CNS vasculitis, recurrent neurological&#xD;
        symptoms, and clinical confirmation by a Neurologist (e.g., Dr. Rama Gourimeni) AND failure&#xD;
        of at least 3 months of oral or IV cytoxan.&#xD;
&#xD;
        OR&#xD;
&#xD;
        Pulmonary or neurovascular Sjogrens with positive SSA/SSB confirmed by a rheumatologist and&#xD;
        neurologist (if CNS involved) or pulmonologist (if lungs involved) and either recurrent&#xD;
        neurologic attacks or progressive pulmonary compromise (dyspnea on exertion, decreased DLCO&#xD;
        or CT findings of active disease) despite at least 6 months of intravenous monthly pulse&#xD;
        cyclophosphamide.&#xD;
&#xD;
          -  3. Patient eligibility must be confirmed by two Rheumatologists. For patients with&#xD;
             neurovascular Behcets, eligibility need only be confirmed by a neurologist.&#xD;
&#xD;
          -  4. A minimum CD34+ cell dose of 2.0 x 10e6/kg post-selection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Significant end organ damage such as:&#xD;
&#xD;
               1. LVEF &lt;40% or deterioration of LVEF during exercise test on MUGA or echocardiogram&#xD;
                  unless due to active disease.&#xD;
&#xD;
               2. Untreated life-threatening arrhythmia.&#xD;
&#xD;
               3. Active ischemic heart disease or heart failure.&#xD;
&#xD;
               4. DLCO &lt; 40% of predicted value unless due to active disease.&#xD;
&#xD;
               5. Serum creatinine &gt; 2.5 mg/dl, unless due to active disease.&#xD;
&#xD;
               6. Liver cirrhosis, transaminases &gt;3x of normal limits, or bilirubin &gt;2.0 unless due&#xD;
                  to Gilberts disease.&#xD;
&#xD;
          -  2. HIV positive.&#xD;
&#xD;
          -  3. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the&#xD;
             investigators would jeopardize the ability of the patient to tolerate aggressive&#xD;
             treatment.&#xD;
&#xD;
          -  4. Prior history of malignancy except localized basal cell or squamous skin cancer.&#xD;
             Other malignancies for which the patient is judged to be cured by local surgical&#xD;
             therapy, such as (but not limited to) head and neck cancer, or stage I or II breast&#xD;
             cancer will be considered on an individual basis.&#xD;
&#xD;
          -  5. Positive pregnancy test, inability or unable to pursue effective means of birth&#xD;
             control, failure to willingly accept or comprehend irreversible sterility as a side&#xD;
             effect of therapy.&#xD;
&#xD;
          -  6. Psychiatric illness or mental deficiency making compliance with treatment or&#xD;
             informed consent impossible.&#xD;
&#xD;
          -  7. Inability to give informed consent.&#xD;
&#xD;
          -  8. Active infection, excluding asymptomatic bacteruria or vaginal candidiasis.&#xD;
&#xD;
          -  9. Active hepatitis B (HBSAg positive) or active hepatitis C (PCR positive blood&#xD;
             lymphocytes).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>January 15, 2006</study_first_submitted>
  <study_first_submitted_qc>January 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <results_first_submitted>June 20, 2017</results_first_submitted>
  <results_first_submitted_qc>October 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2018</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous Stem Cell Transplant</title>
          <description>Autologous Stem Cell Transplant will be performed on eligible patients&#xD;
Autologous Stem Cell Transplant: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning</description>
        </group>
        <group group_id="P2">
          <title>Allogeneic Stem Cell Transplant</title>
          <description>Allogeneic Stem Cell Transplant will be performed on eligible patients&#xD;
Allogeneic Stem Cell Transplant: Allogeneic Stem Cell Transplant will be performed after conditioning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous Stem Cell Transplant</title>
          <description>Autologous Stem Cell Transplant will be performed on eligible patients&#xD;
Autologous Stem Cell Transplant: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning</description>
        </group>
        <group group_id="B2">
          <title>Allogeneic Stem Cell Transplant</title>
          <description>Allogeneic Stem Cell Transplant will be performed on eligible patients&#xD;
Allogeneic Stem Cell Transplant: Allogeneic Stem Cell Transplant will be performed after conditioning</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.43" spread="12.03"/>
                    <measurement group_id="B3" value="40.43" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>Survival</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Stem Cell Transplant</title>
            <description>Autologous Stem Cell Transplant will be performed on eligible patients&#xD;
Autologous Stem Cell Transplant: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning</description>
          </group>
          <group group_id="O2">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Allogeneic Stem Cell Transplant will be performed on eligible patients&#xD;
Allogeneic Stem Cell Transplant: Allogeneic Stem Cell Transplant will be performed after conditioning</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Survival</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months, 1 year, then yearly for at least 5 years post transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous Stem Cell Transplant</title>
          <description>Autologous Stem Cell Transplant will be performed on eligible patients&#xD;
Autologous Stem Cell Transplant: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning</description>
        </group>
        <group group_id="E2">
          <title>Allogeneic Stem Cell Transplant</title>
          <description>Allogeneic Stem Cell Transplant will be performed on eligible patients&#xD;
Allogeneic Stem Cell Transplant: Allogeneic Stem Cell Transplant will be performed after conditioning</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV Hepatitis</sub_title>
                <description>One participant died of CMV hepatitis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bowel obstruction</sub_title>
                <description>Two years after transplant had bowel obstruction due to pre transplant surgical scars-</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Swine flu</sub_title>
                <description>One patient diagnosed with swine flu, requiring transient face mask oxygen and recovered.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Aspergillus</sub_title>
                <description>One patient 4 years after transplant relapsed and was started on actemra. After 2 years of actemra ( a TNF inhibitor) patient developed aspergillus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pseudomonas pneumonia</sub_title>
                <description>One patient 4 years after transplant relapsed and was started on actemra. After 2 years of actemra ( a TNF inhibitor) patient developed pseudomonas pneumonia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects enrolled</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Richard Burt</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-4960</phone>
      <email>rburt@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

